Wealthspire Advisors LLC Acquires 6,332 Shares of Stryker Corporation $SYK

Wealthspire Advisors LLC boosted its holdings in shares of Stryker Corporation (NYSE:SYK) by 112.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,958 shares of the medical technology company’s stock after purchasing an additional 6,332 shares during the quarter. Wealthspire Advisors LLC’s holdings in Stryker were worth $4,731,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC increased its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the period. Diversify Advisory Services LLC acquired a new stake in Stryker in the 1st quarter worth $200,000. IFP Advisors Inc increased its holdings in shares of Stryker by 17.3% during the 1st quarter. IFP Advisors Inc now owns 2,626 shares of the medical technology company’s stock worth $979,000 after purchasing an additional 387 shares during the period. HighPoint Advisor Group LLC raised its position in shares of Stryker by 6.5% during the first quarter. HighPoint Advisor Group LLC now owns 4,638 shares of the medical technology company’s stock valued at $1,720,000 after buying an additional 282 shares during the last quarter. Finally, Obermeyer Wealth Partners lifted its stake in shares of Stryker by 9.0% in the first quarter. Obermeyer Wealth Partners now owns 2,896 shares of the medical technology company’s stock valued at $1,078,000 after buying an additional 239 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $359.53 on Wednesday. The firm has a market capitalization of $137.49 billion, a P/E ratio of 47.62, a P/E/G ratio of 2.66 and a beta of 0.94. The stock has a fifty day moving average price of $370.62 and a two-hundred day moving average price of $381.03. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Barclays upped their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Rothschild & Co Redburn assumed coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the transaction, the chief accounting officer owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 522,453 shares of company stock valued at $185,516,867. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.